Notice Regarding the Resignation of an Outside Director

Hyogo, Japan – September 15, 2026 – JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”) today announced the resignation of the following Outside Director.

1. Resignation of Director
   Outside Director (Independent): Philippe Fauchet
   
2. Effective Date of Resignation
   September 15, 2026
   
3. Reason for Resignation
   The resignation is due to personal reasons.
   
4. Other Matters
   After the resignation of the Outside Director, the Company continues to satisfy the number of Directors required under applicable laws and regulations and the articles of incorporation.

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world’s most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR’s global website: https://jcrpharm.com/